| Institution |
Name |
Project |
Amount Awarded |
Dates |
| The University of Leeds |
Professor Terence Rabbitts |
Mouse modelling of prostate cancer through TMP-ETS family fusion genes |
£245,761 |
2010-13 |
| The University of Ulster |
Dr Paul Thompson |
A novel chemoprotective role for vitamin D in prostate cancer |
£164,754 |
2010- 2013 |
| The University of Oxford |
Dr Thomas Helleday |
Exploiting defects in DNA repair for treatment of prostate cancer |
£248,975 |
2010-2013 |
| The Institute of Cancer Research |
Professor Colin Cooper |
Multiplex detection of prognostic biomarkers in the urine of patients on Active Surveillance: a pilot study |
£47,860 |
2010- 2011 |
| University College London |
Dr Roberto Alonzi |
A Phase Ib/II trial of Prostate Radiotherapy in Conjunction with Carbogen and Nicotinamide (PROCON) |
£243,712 |
2010- 2013 |
| The University of Newcastle |
Professor Craig Robson |
The role of ubiquitin in androgen receptor function in prostate cancer
|
£195,485 |
2010- 2013 |
| The University of Belfast |
Dr Helen McCarthy |
A bio-inspired gene therapy approach to treat metastatic prostate cancer
|
£95,314 |
2010- 2013 |
| The University of Bristol |
Professor David Bates |
Alternative splicing as a novel drug target for prostate cancer
|
£98,889 |
2010- 2013 |
| The University of Belfast |
Dr Anna Gavin |
Living with and beyond Prostate Cancer: Does more investigation result in better health? A study of the impact on men of increased and variable investigation and treatment of prostate cancer in the Island of Ireland.
|
£299,648 |
2010- 2013 |
| TBC |
TBC |
The Prostate Cancer Charity has this year separately "ear-marked" £150,000 specifically for funding psychosocial research. This is an area in which the Charity wishes to invest more targeted research activity. As a result, we have taken the initiative to drive this research field forwards by commissioning project(s) specifically tailored towards key issues that have been identified by the Charity as of particular significance to people affected by prostate cancer. Further information will be available shortly.
|
£150,000 |
TBC |
| Institution |
Name |
Project |
Amount Awarded |
Dates |
| Institute of Cancer Research and Royal Marsden Hospital |
Dr Johann de Bono |
Finding out why the new drug Abiraterone, developed to treat men with advanced prostate cancer, eventually stops working |
£248,028 |
2009-12 |
| Cancer Research UK Cambridge Research Institute |
Professor David Neal |
Screening for novel factors involved in the prostate cancer response to hormones |
£26,000 |
2009-10 |
| Centre for Health Sciences, Barts and the London School of Medicine and Dentistry |
Professor Clive Seale |
The public face of prostate cancer in the UK |
£66,295 |
2009-12 |
| School of Health Sciences, University of Southampton |
Dr Mandy Fader |
A trial of devices designed to prevent or contain persistent urinary leakage following prostate cancer surgery |
£106,517 |
2009-11 |
| Academic Urology Unit, Institute of Cancer Research and Royal Marsden Hospital |
Dr Chris Parker |
Examination of biomarkers in prostate biopsies from patients in two radiotherapy trials |
£126,801 |
2009-11 |
| School of Biomedical Sciences, University of Ulster in Coleraine |
Professor Stephanie McKeown |
Understanding prostate cancer response to the hormone therapy bicalutamide
|
£96,401 |
2009-12 |
| Centre for Infection & Immunity, Queen’s University, Belfast |
Dr Andrew McDowell |
Bacterial infection as a potential cause of prostate cancer
|
£157,943 |
2009-12 |
| Department of Oncology, Imperial College London |
Dr Dmitry Pshezhetskiy and Dr Justin Sturge |
How does the enzyme SK1 help prostate cancer spread to other parts of the body?
|
£123,632 |
2009-12 |
| Department of Pharmacy & Pharmacology at the University of Bath |
Professor Michael Threadgill |
A new approach to delivery of super potent drugs to prostate tumours
|
£101,992 |
2009-12 |
| Institution |
Name |
Project |
Amount Awarded |
Dates |
| Queen’s Institute for Medical Research, Edinburgh |
Dr Axel Thomson |
Finding out how non-tumour stromal cells control human prostate tumour growth |
£145,738 |
2008-11 |
| Edinburgh Cancer Research Centre |
Professor Fouad Habib |
The use of nitric oxide in combination with radiotherapy as a new treatment for prostate cancer |
£108,204 |
2008-10 |
| The Institute of Cancer Research, Sutton |
Professor Colin Cooper |
Developing a way to predict the aggressiveness of prostate cancer |
£152,475 |
2008-11 |
| Imperial College, London |
Dr Lakjaya Buluwela |
Studying the role the GNMT protein plays in prostate cancer |
£102,220 |
2008-11 |
| Institution |
Name |
Project |
Amount Awarded |
Dates |
| The University of Sheffield |
Dr Munitta Muthana |
Gene therapy for advanced prostate cancer |
£210,564 |
2007-10 |
| The Institute of Cancer Research, Sutton |
Dr Chris Parker |
Identifying biomarkers that will help predict how individuals might be affected by their prostate cancer |
£158,635 |
2007-10 |
| Imperial College, London |
Dr Dmitry Pshezhetskiy |
Researching a molecule that might make prostate cancer cells more susceptible to both chemotherapy and radiotherapy |
£118,893 |
2007-10 |
| Imperial College, London |
Dr Justin Sturge |
Studying a molecule which might be a potential target for treatments that stop prostate cancer spreading to the bone |
£97,093 |
2007-10 |
| Beatson Cancer Centre, Glasgow |
Professor Hing Leung |
Developing a possible drug treatment for aggressive prostate cancer |
£73,690 |
2007-09 |
| Institution |
Name |
Project |
Amount Awarded |
Dates |
| The Prostate Cancer Research Group, Hammersmith Hospital |
Dr Charlotte Bevan |
Downstream targets of androgen signalling: a proteomic approach |
£543,424 |
July 2004 - April 2007 |
| |
Dr Robert Kypta |
Investigation of Wnt function in the normal prostate and in prostate cancer. Investigation of sFRP-1 and Wnt11 function in prostate cancer. Beta-catenin localisation and function in prostate cancer cells |
£622,734 |
Nov 2004 - Oct 2008 |
| |
Dr Tahereh Kamalati |
Development of recombinant single chain Fv antibodies to human prostate cells for prostate research and therapy |
£201,379 |
July 2004 – Oct 2006 |
| |
Dr Simak Ali and Dr Laki Buluwela |
Targeting of histone deacetylation to androgen regulated genes for therapeutic approaches in prostate cancer |
£186,279 |
July 2004 - June 2007 |
| The University of Leicester |
Paul Sinfield |
Research the support and information needs of carers for men with prostate cancer |
£83,564 |
2007-08 |
| Imperial College, London |
Professor Mustafa Djamgoz |
Researching a gene that might be important in the early identification of aggressive prostate cancer, and also in creating a long lasting treatment for it |
£51,574 |
2007-08 |
